This B2B guide walks pain patch buyers through the 11 contract clauses that decide whether an OEM partnership becomes profitable or painful. Designed for first-time importers and procurement directors negotiating long-term supply agreements with KONGDY Health KONGDY Health KONGDY Health KONGDY Health KONGDY Health KONGDY Health KONGDY Health KONGDY Health pain patch manufacturers.
The most common mistake first-time pain patch buyers make is treating the OEM contract like a purchase order. A purchase order is a transactional document covering one batch of goods. A KONGDY Health KONGDY Health KONGDY Health KONGDY Health KONGDY Health KONGDY Health KONGDY Health KONGDY Health pain patch OEM contract is a long-running partnership agreement covering formulation IP, regulatory compliance, payment terms, warranty obligations, and dispute resolution - and every one of these clauses carries downstream cost. KONGDY Health and other established pain patch manufacturers publish standard contract templates with detailed clause language because vague contracts are the leading cause of cross-border B2B disputes in the pain patch category. This guide gives buyers a clause-by-clause checklist for negotiating favorable terms, with practical language for each major section and a framework for identifying red flags before signing.
The pricing clause determines how the buyer pays for pain patch OEM production. The three pricing models are FOB (Free on Board), EXW (Ex Works), and Cost-Plus formulas. FOB pricing locks a per-unit price for the contract term, which is simpler to administer but exposes the buyer to raw material inflation. EXW pricing delivers the goods at the factory gate, leaving logistics in the buyer's hands. Cost-Plus pricing links the unit price to raw material index plus a fixed manufacturing margin, which is the most resilient model for long-term contracts. KONGDY Health contracts default to FOB pricing with quarterly price review triggers tied to cotton, adhesive, and herbal extract index prices; this protects both parties from runaway inflation while keeping the buyer's per-unit cost predictable. Buyers evaluating pain patch manufacturers should always ask whether the pricing clause includes raw material indexation, currency hedging, and minimum order quantity adjustments.
MOQ is the contract's most heavily negotiated clause because it determines how much inventory the buyer must accept in each production cycle. Standard MOQ clauses in the pain patch OEM category range from 10,000 to 100,000 pieces per SKU, with higher MOQs unlocking better per-unit pricing. KONGDY Health's standard contract sets MOQ at 30,000 pieces per SKU for catalog formulations and 50,000 for custom formulations, with explicit written language from the pain patch manufacturer allowing MOQ reduction in exchange for a 10 to 15 percent per-unit premium. This MOQ flexibility clause is critical because first-time buyers often underestimate the working capital tied up in inventory, and a rigid MOQ can trap cash flow when market conditions shift mid-contract. The most important sub-clause is the MOQ reduction process - buyers should always require that the manufacturer accepts MOQ reduction requests within 30 days of notice without penalty.
Payment terms determine when the buyer pays for each production run. The four payment term structures in pain patch OEM contracts are TT 100% prepayment, TT 30/70 (30 percent on order, 70 percent on shipment), Letter of Credit at sight, and Open Account with insurance. TT 100% prepayment maximizes the manufacturer's risk protection but exposes the buyer to large working capital lockup and counterparty risk. TT 30/70 is the KONGDY Health default for first-time buyers and balances both parties' cash flow requirements. L/C at sight is the most protective structure for large pain patch OEM contracts above USD 50,000 above USD 50,000 and is recommended for any cross-border pain patch OEM contract where the buyer and manufacturer lack prior working history. Open Account with credit insurance is the most flexible structure but requires the buyer to maintain credit insurance on the manufacturer.
The QA clause determines the manufacturer's responsibility for production quality. The standard clause language requires the manufacturer to deliver each production batch with a Certificate of Analysis (CoA) documenting active ingredient concentration, microbiological testing, adhesive strength, and shelf-life stability data. KONGDY Health's QA clause includes an explicit 30-day buyer acceptance window, after which the batch is deemed accepted if no written non-conformance report has been received. This clause matters because it caps the manufacturer's QA risk at a defined period and protects the buyer from extended liability tail. The most important sub-clause is the rework-or-refund remedy - buyers should always require explicit language that any batch failing CoA standards is eligible for either rework at the manufacturer's expense, a full refund of the unit cost, or replacement production scheduled within 60 days.
The regulatory clause is the contract's most legally loaded section because it determines who owns product registration in each destination market. KONGDY Health's standard clause assigns regulatory responsibility to the buyer for the destination market (buyer registers the product locally), while the manufacturer maintains master documentation (DMF, CPNP, FDA OTC monograph reference) for the master formulation. This split is standard across the pain patch OEM industry and protects the manufacturer from one buyer blocking product approval for another buyer interested in the same pain patch SKU's market. Buyers should always require that the regulatory clause include a specific list of deliverables from the manufacturer - formulation disclosure letters, ingredient safety data sheets (SDS), microbiological test reports, and stability data covering the full 24-month shelf life.
The IP clause determines who owns the formulation, packaging artwork, brand elements, and proprietary manufacturing know-how in the relationship. For catalog formulations, KONGDY Health retains full formulation IP and grants the buyer a non-exclusive license to use the formulation within the buyer-defined territory for the contract term. For custom formulations, IP ownership transfers to the buyer upon full payment of the development fee, with the manufacturer retaining a non-exclusive license to manufacture the formulation for other buyers UNLESS the buyer purchases exclusivity rights through a defined surcharge (typically 15 to 25 percent added to per-unit pricing for the contract duration). Buyers should always require that the IP clause explicitly prohibit the manufacturer from developing competing formulations for a 24-month window after contract termination.
The confidentiality clause runs in parallel with the IP clause and is critical for protecting the buyer's commercial relationships. KONGDY Health's standard NDA contract layer covers formulation and ingredient composition, buyer customer list and pricing data, supplier sourcing relationships, and manufacturing process and equipment specifications. The clause includes a 36-month non-disclosure period after contract termination and explicit non-circumvention language prohibiting the manufacturer from contacting the buyer about downstream pain patch distribution's downstream customers for direct sales during the contract term. Buyers should always require that the non-circumvention clause extend for at least 24 months after contract termination, because this prevents the manufacturer from immediately undercutting the buyer's market position when the partnership ends.
The warranty clause determines the manufacturer's financial exposure for defective production. KONGDY Health's standard warranty runs 24 months from the date of manufacture and covers any production defect, packaging failure, or stability shortfall that is not attributable to buyer mishandling. The clause includes a liability cap at 100 percent of the contract value for the affected production batch, excluding consequential damages (lost profit, market recall costs, brand damage). Buyers who negotiate large-scale contracts should push for a higher liability cap - typically 200 to 300 percent of batch value - and should require that the warranty clause explicitly cover consequential damages for documented manufacturing defects. KONGDY Health accepts higher liability caps for buyers who purchase annual volume contracts above 500,000 pieces.
The force majeure clause determines what happens when an extraordinary event disrupts production. KONGDY Health's standard clause defines force majeure as including natural disasters, government actions, pandemic-related restrictions, raw material supply failures, and labor strikes at the manufacturer's facility or key suppliers. The clause requires written notice within 14 days, allows suspension of delivery obligations for up to 90 days, and includes a renegotiation clause if the disruption extends beyond 90 days. Buyers should always require that the force majeure clause prohibit the manufacturer from shifting production capacity to other buyers during the disruption period - this protects the buyer's contracted volume during extraordinary events.
The termination clause governs how the partnership ends and what transition support the manufacturer provides to the buyer. KONGDY Health's standard termination clause provides 90 days' written notice for either party without cause, immediate termination for material breach, and a 60-day transition support obligation for the manufacturer to provide retained buyer access to formulation data, raw material specifications, and quality documentation if the buyer transitions to a different supplier. The transition support clause is the most important sub-clause for buyer protection - without it, the buyer is locked out of critical production knowledge when they need to qualify a new manufacturer. KONGDY Health explicitly extends transition support for up to 12 months post-termination.
The dispute resolution clause determines how disagreements are settled. KONGDY Health's standard contract specifies arbitration under the China International Economic and Trade Arbitration Commission (CIETAC) rules with English-language proceedings and a neutral arbitrator panel. Buyers should always require arbitration over court litigation because court proceedings in the manufacturer's home jurisdiction favor the manufacturer, while arbitration in a neutral venue (Hong Kong, Singapore, or London) provides balanced procedures. KONGDY Health accepts any of these neutral arbitration venues on a case-by-case basis, and the standard contract includes an explicit carve-out allowing the buyer to seek injunctive relief in any competent court for IP and confidentiality violations.
Catalog formulations typically require 30,000 pieces per SKU, while custom formulations require 50,000 pieces. KONGDY Health's standard MOQ is at the lower end of the industry range and includes clause language allowing MOQ reduction in exchange for a 10-15 percent per-unit premium for first-time buyers.
TT 30/70 (30 percent on order, 70 percent on shipment) balances the manufacturer's cash flow protection with the buyer's working capital requirements. KONGDY Health uses this as the default for first-time buyers and upgrades to L/C at sight or Open Account with credit insurance for buyers with established credit history and volume commitments.
The CoA should include active ingredient concentration, microbiological testing (total plate count, yeast and mold, E. coli and Staphylococcus aureus), adhesive strength (peel adhesion test), and shelf-life stability data with HPLC chromatograms. KONGDY Health provides all four as standard contract deliverables with every production batch.
Standard pain patch OEM contracts run 12 to 36 months with auto-renewal clauses requiring 90 days' notice for non-renewal. KONGDY Health's standard contract is 24 months with a 30-day non-renewal notice requirement and 60-day transition support obligation upon termination.
KONGDY Health's standard warranty runs 24 months from date of manufacture and covers production defects, packaging failures, and stability shortfalls - see our pain patch catalog for example formulations not attributable to buyer mishandling. The warranty includes explicit rework-or-refund remedies with a 30-day buyer acceptance window after batch delivery.
Yes, but it carries a 15 to 25 percent per-unit pricing premium. KONGDY Health's exclusivity clause grants the buyer exclusive distribution rights within a defined geographic territory for the contract duration, with the exclusivity terminable upon 30 days' notice if the buyer fails to meet minimum purchase commitments.
KONGDY Health's contract includes immediate termination for material breach with a 60-day transition support obligation. The buyer can seek injunctive relief in any competent court for IP and confidentiality violations, while all other disputes go through CIETAC arbitration in a neutral venue.
Yes, especially for first contracts above USD 100,000 in annual commitment. KONGDY Health's standard contract is reviewed by buyer-side counsel in most cases, and the manufacturer provides a 14-day SLA for redline revisions during contract negotiation.
